10058-F4: Enabling Precision c-Myc-Max Inhibition in Apoptosis and Cancer Research

Principle and Setup: Targeting c-Myc-Max Dimerization in Cellular Models

As a novel small-molecule, cell-permeable c-Myc-Max dimerization inhibitor, 10058-F4 directly disrupts the interaction between c-Myc and Max transcription factors. This inhibition prevents c-Myc-driven transcriptional programs by blocking DNA binding, leading to decreased c-Myc mRNA and protein expression, cell cycle arrest, and apoptosis via the mitochondrial pathway. The compound’s versatility has been demonstrated in both in vitro and in vivo contexts, notably in acute myeloid leukemia (AML) cell lines (HL-60, U937, NB-4) and human prostate cancer xenografts (DU145, PC-3) in SCID mice.

Recent advances, such as those outlined in the study MEK1/2 kinases cooperate with c-Myc:MAX to prevent polycomb repression of TERT in human pluripotent stem cells, further elucidate the pivotal role of c-Myc-Max dimerization in transcriptional regulation, telomerase maintenance, and cellular self-renewal. Here, 10058-F4’s ability to modulate epigenetic marks and telomerase expression underscores its critical utility for stem cell and cancer biology research.

Experimental Workflow: Stepwise Use of 10058-F4 in Apoptosis and Transcription Assays

1. Compound Preparation and Handling

• Solubilization: 10058-F4 is supplied as a solid and is highly soluble in DMSO (≥24.9 mg/mL) or ethanol (≥2.64 mg/mL), but insoluble in water. Prepare fresh stock solutions immediately before use; avoid long-term storage of solutions as stability may decrease.
• Aliquoting: Store aliquots at -20°C to prevent repeated freeze-thaw cycles. For consistency, pre-warm DMSO or ethanol to room temperature before dissolving the compound.

2. Cell Treatment Protocol

• Cell Line Selection: 10058-F4 has established efficacy in AML cell lines (HL-60, U937, NB-4) as well as solid tumor models (DU145, PC-3). Plate cells at the recommended density for your apoptosis or proliferation assay.
• Dosing Strategy: For apoptosis induction, dose cells with 10058-F4 at concentrations ranging from 10 μM to 100 μM. Significant dose-dependent apoptosis is observed at 100 μM after 72 hours in AML lines, as evidenced by increased Annexin V staining and caspase activation.
• Controls: Include vehicle-only (DMSO/ethanol) controls and, where possible, positive controls for apoptosis (e.g., staurosporine).

3. Downstream Assays

• Apoptosis Assays: Assess apoptosis using Annexin V/PI flow cytometry, TUNEL staining, or caspase-3/7 activity assays. Mitochondrial cytochrome C release and modulation of Bcl-2 family proteins can be quantified by Western blot or ELISA.
• Transcriptional Profiling: Quantify c-Myc, Max, and TERT mRNA by RT-qPCR. ChIP-qPCR can interrogate histone modifications (H3K27me3, H3K27ac) at the TERT promoter, as highlighted in the aforementioned reference study. Assess protein levels by Western blotting, focusing on c-Myc, Max, and apoptosis markers.
• In Vivo Application: For xenograft studies, 10058-F4 can be administered intravenously. In SCID mice bearing DU145 or PC-3 tumors, repeated dosing led to variable but significant tumor growth inhibition, providing a clinically relevant benchmark for translational research.

Advanced Applications and Comparative Advantages

1. Unraveling c-Myc-Driven Oncogenic Pathways

10058-F4’s cell-permeable design enables rapid and reversible disruption of the c-Myc/Max heterodimerization pathway, making it superior to genetic knockdown approaches for temporal studies. As reported in the article 10058-F4: Unraveling c-Myc/Max Disruption for Precision Apoptosis, this compound allows researchers to dissect the mitochondrial apoptosis pathway in real time, with direct impacts on Bcl-2 family regulation and cytochrome C dynamics.

2. Telomerase and TERT Regulation in Stem Cells

The recent reference study (Kotian et al., 2024) demonstrates that low-dose c-Myc/Max dimerization inhibition with 10058-F4 induces rapid H3K27me3 accumulation at the TERT promoter and represses TERT transcription in human pluripotent stem cells. This positions 10058-F4 as a unique tool for interrogating telomere biology and epigenetic regulation during early development and cellular aging.

3. Apoptosis Assays in Hematological and Solid Tumors

Quantitative studies have shown that 10058-F4 induces apoptosis in AML cell lines in a dose- and time-dependent manner, with significant effects at 100 μM after 72 hours. In vivo, APExBIO-supplied 10058-F4 effectively suppressed tumor growth in prostate cancer xenografts, supporting its translational relevance (APExBIO: Reliable c-Myc-Max Dimerization Inhibitor).

4. Comparative Analysis with Related Tools

Compared to siRNA or CRISPR-based c-Myc inhibition, 10058-F4 provides rapid, tunable, and reversible effects, minimizing compensatory cellular adaptations. As explored in Disrupting c-Myc/Max Dimerization: Strategic Pathways, its specificity and cell permeability distinguish it from less targeted small molecules or peptide-based inhibitors, making it ideal for both short- and long-term studies of c-Myc transcription factor inhibition.

Troubleshooting and Optimization: Maximizing Data Quality

1. Compound Handling and Solubility

• Issue: Precipitation or incomplete dissolution.
• Solution: Use freshly prepared DMSO or ethanol; sonicate for 5-10 minutes if necessary. Avoid aqueous buffers for initial solubilization.

• Issue: Loss of activity with stored solutions.
• Solution: Prepare single-use aliquots and use immediately. Discard unused solutions after each experiment.

2. Assay Optimization

• Cell Viability: Confirm cell health prior to treatment. High DMSO concentrations (>0.5%) can induce cytotoxicity—keep vehicle concentrations minimal and equal across all conditions.
• Dose Titration: Start with a dose range (10–100 μM). Pilot studies can identify the optimal concentration for your cell type and endpoint.
• Time Course: Standard apoptosis induction is observed after 72 hours, but earlier time points (24–48 hours) may be informative for certain readouts (e.g., early apoptosis, transcriptional repression).
• Readout Selection: Pair apoptosis assays with transcriptional profiling for a comprehensive mechanistic understanding. For TERT regulation studies, include ChIP-qPCR for histone modifications and qPCR for TERT and c-Myc mRNA levels.

3. In Vivo Considerations

• Administration: Use intravenous injection for optimal bioavailability in xenograft models. Monitor mice for signs of toxicity and adjust dosing intervals as needed.
• Endpoints: Tumor volume, apoptosis markers, and c-Myc/TERT expression should be assessed in parallel to provide mechanistic and efficacy data.

Future Outlook: Next-Generation Pathways for c-Myc and Telomerase Modulation

The mechanistic clarity and translational potential of 10058-F4 position it as a foundational tool for interrogating oncogenic transcription, apoptosis, and telomerase regulation. Its role in disrupting the c-Myc/Max heterodimerization pathway is likely to expand beyond cancer and stem cell biology into regenerative medicine, aging research, and epigenetic therapy development.

Emerging studies, including those cited in 10058-F4: Targeting c-Myc/Max Dimerization to Modulate TERT, highlight the compound’s ability to bridge mitochondrial apoptosis with chromatin-level regulation of telomerase, opening new avenues for precision medicine and combinatorial therapeutic strategies. As more is learned about the c-Myc/Max axis and its interplay with MAPK signaling, tools like APExBIO’s 10058-F4 will remain at the forefront of experimental innovation.

Conclusion

10058-F4, available from APExBIO, offers a unique, highly validated approach to inhibiting c-Myc-Max dimerization and modulating apoptosis and telomerase regulation in a broad array of experimental systems. Its proven performance in AML, prostate cancer, and stem cell models, combined with robust troubleshooting and workflow guidance, make it an indispensable reagent for researchers seeking actionable insights into the c-Myc/Max heterodimer disruption pathway, mitochondrial apoptosis, and c-Myc transcription factor inhibition.